/ /

ModernMedicine Resource Center More Topics


The number of monitoring visits for patients treated for localized primary melanoma can be reduced considerably, without having much effect on spotting any recurrent or new melanomas, according to a study. 

Melanoma - Diagnosis & Therapy

Newly discovered dermoscopy features differentiate melanoma in situ from benign lesions, shows a study in JAMA Dermatology.
Knowing how to recognize and manage the various forms of conjunctival pigmented lesions can literally mean the difference between life and death in some cases.
A new genetic test can identify patients with nonmetastatic melanoma who are at high risk of recurrence, according to validation data presented at the 2013 summer meeting of the American Academy of Dermatology.
Many pediatric patients with melanoma do not demonstrate symptoms falling within the ABCDE detection criteria, researchers say.
There has been a rapid revolution in the treatment of metastatic melanoma since the identification of driver oncogenes such as BRAF and its mutations more than a decade ago, according to a clinical researcher at the Vanderbilt-Ingram Cancer Center, Nashville, Tenn.
The results of the first Multicenter Selective Lymphadenectomy Trial (MSLT-1) seem to indicate that survival in patients with intermediate thickness melanoma and metastatic disease in the regional nodes can be improved if early lymph node dissection is performed when a positive sentinel node is identified.
Sentinel lymph node (SLN) status represents the most important prognostic factor for disease-specific survival in primary cutaneous melanomas, said Christopher K. Bichakjian, M.D., at the 70th annual meeting of the American Academy of Dermatology. However, he says, its impact on overall survival remains unclear.
Several newly approved therapies have changed and are continuing to change the treatment of melanoma therapy so that it is no longer the "black sheep" of cancer therapy, according to Adil Daud, M.D.
Although ipilimumab (Yervoy, Bristol-Myers Squibb) has been a tremendous advance for patients with metastatic melanoma, only a subset of patients benefits from treatment.